RFL Overview

Continuation of Phase 3 Study: Rafael Holdings' subsidiary, Cyclo Therapeutics, will continue its pivotal phase 3 TransportNPC study for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C1 (NPC1) after a positive interim analysis by an independent Data Monitoring Committee (DMC).

Trappsol® Cyclo™ Overview: Trappsol® Cyclo™, administered intravenously, aims to address the root cause of NPC1 by mobilizing cholesterol from cells, and has shown a favorable safety profile consistent with earlier studies.

Real Estate Sector Performance: Real estate shares have shown relative strength, increasing by approximately 1% overall, with Rafael Holdings rising by about 10.7% and Jones Lang LaSalle up by around 2.3% on Thursday.

Market Commentary Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.

Rights Offering Results: Rafael Holdings, Inc. successfully closed a $25 million rights offering, resulting in subscriptions for 3,130,480 shares of Class B common stock, generating gross proceeds of approximately $4 million. CEO Howard Jonas and affiliates will purchase unsubscribed shares through a backstop private placement totaling about $21 million.

Use of Proceeds: The funds raised from the rights offering and backstop private placement are intended to support regulatory approval efforts and potential launch of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, pending positive results from ongoing clinical trials.

Rights Offering Announcement: Rafael Holdings, Inc. has announced a rights offering for holders of Class A and B Common Stock, allowing them to purchase shares at a subscription price of $1.28 each, with the subscription period running from May 13 to May 29, 2025.

Eligibility and Participation Details: To participate, holders must be recorded as of May 9, 2025, and former Cyclo Therapeutics shareholders need to exchange their shares for Class B common stock before this date; Howard Jonas will also purchase any unsubscribed shares under a Standby Purchase Agreement.

Upcoming Stock Splits: Several companies, including Tasman Resources Ltd., Sol-Gel Technologies, and NewGenIVF Group Ltd., are set to undergo reverse stock splits from May 5 to May 9 to maintain compliance with Nasdaq's listing requirements or improve share liquidity.

Company Details: The article highlights specific details of each company's stock split, including the ratio of the split and the effective date, emphasizing their focus areas such as biotechnology, dermatology, and reproductive services.